Liu et al. from MD Andersons Cancer center conducted a Phase 1/2 trial at using HLA mismatched anti-CD19 CAR-NK, derived from cord blood and transduced with a retroviral vector expressing anti-CD19 CAR, IL-15, and inducible caspase 9, which were administered to 11 heavily pretreated patients with NHL (n = 6) and CLL/RT (n = 5) (median of four prior lines of therapy). The gene discussed is CD19; the disease is non-Hodgkin lymphoma.